|
Sign In to gain access to subscriptions and/or personal tools.
|
Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations
T Avcin
Department of Pediatrics, University Medical Center Ljubljana, Slovenia
R Cimaz
Department of Pediatrics, Istituti Clinici di Perfezionamento, Milan, Italy
P L Meroni
IRCCS Istituto Auxologico Italiano, Department of Internal Medicine, University of Milan, Via L. Ariosto 13, 20145 Milan, Italy. pierluigi.meroni{at}unimi.it
In recent years, antiphospholipid antibodies (aPL) and their associated clinical features have been recognized increasingly in various pediatric autoimmune and non-autoimmunediseases. Pathogenic mechanisms involved in pediatric antiphospholipid syndrome (APS) appear to be the same as inadults. However, since pediatric patients do not have prothrombotic risk factors present in adults, there clearly are differences in the spectrum of clinical findings. The frequency of aPL-related thrombotic events is generally low in pediatric populations. On the other hand, various commonly acquired infections are likely to be responsible for higher percentage of non-pathogenic and transient aPL in childhood. Such points have to be considered in clinical judgment of elevated aPL in children. In this review we summarize the recent data on the prevalence and clinical significance of aPL in neonates, children and adolescents.
Key Words: antiphospholipid antibodies antiphospholipid syndrome childhood
Lupus, Vol. 11, No. 1,
4-10 (2002)
DOI: 10.1191/0961203302lu146rr

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A Tincani, M Filippini, M Scarsi, M Galli, and P. Meroni
European attempts for the standardisation of the antiphospholipid antibodies
Lupus,
September 1, 2009;
18(10):
913 - 919.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Raza, S. A. Epstein, M. Pao, and D. L. Rosenstein
Mania: Psychiatric Manifestations of the Antiphospholipid Syndrome
Psychosomatics,
September 1, 2008;
49(5):
438 - 441.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Di Simone, P.L. Meroni, M. D'Asta, F. Di Nicuolo, M.C. D'Alessio, and A. Caruso
Pathogenic role of anti-{beta}2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin
Hum. Reprod. Update,
March 1, 2007;
13(2):
189 - 196.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Shah, M. A. O'Riordan, and S. W. Alexander
Evaluation of Prolonged aPTT Values in the Pediatric Population
Clinical Pediatrics,
May 1, 2006;
45(4):
347 - 353.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A Tincani, D Bompane, E Danieli, and A Doria
Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome)
Lupus,
March 1, 2006;
15(3):
156 - 160.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N Di Simone, E Raschi, C Testoni, R Castellani, M D'Asta, T Shi, S A Krilis, A Caruso, and P L Meroni
Pathogenic role of anti-{beta}2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of {beta}2-glycoprotein I binding to trophoblast cells and functional effects of anti-{beta}2-glycoprotein I antibodies in vitro
Ann Rheum Dis,
March 1, 2005;
64(3):
462 - 467.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P L Meroni, N di Simone, C Testoni, M D'Asta, B Acaia, and A Caruso
Antiphospholipid antibodies as cause of pregnancy loss
Lupus,
September 1, 2004;
13(9):
649 - 652.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M Motta, A Tincani, A Lojacono, D Faden, R Gorla, P Airo, F Neri, A Gasparoni, L Ciardelli, A de Silvestri, et al.
Neonatal outcome in patients with rheumatic disease
Lupus,
September 1, 2004;
13(9):
718 - 723.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Avcin, T. Kveder, B. Rozman, D. W. Branch, J. S. Levine, and J. Rauch
The Antiphospholipid Syndrome
N. Engl. J. Med.,
July 11, 2002;
347(2):
145 - 146.
[Full Text]
[PDF]
|
 |
|
|
|